- Home
- HCM vs SAM Comparison
HCM vs SAM Comparison
Compare HCM & SAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCM
- SAM
- Stock Information
- Founded
- HCM 2000
- SAM 1984
- Country
- HCM Hong Kong
- SAM United States
- Employees
- HCM N/A
- SAM N/A
- Industry
- HCM Biotechnology: Pharmaceutical Preparations
- SAM Beverages (Production/Distribution)
- Sector
- HCM Health Care
- SAM Consumer Staples
- Exchange
- HCM Nasdaq
- SAM Nasdaq
- Market Cap
- HCM 2.6B
- SAM 2.4B
- IPO Year
- HCM N/A
- SAM 1995
- Fundamental
- Price
- HCM $15.10
- SAM $217.69
- Analyst Decision
- HCM Sell
- SAM Hold
- Analyst Count
- HCM 1
- SAM 10
- Target Price
- HCM $13.75
- SAM $246.11
- AVG Volume (30 Days)
- HCM 43.6K
- SAM 178.1K
- Earning Date
- HCM 08-07-2025
- SAM 10-22-2025
- Dividend Yield
- HCM N/A
- SAM N/A
- EPS Growth
- HCM N/A
- SAM N/A
- EPS
- HCM 0.53
- SAM 6.99
- Revenue
- HCM $602,197,000.00
- SAM $2,049,593,000.00
- Revenue This Year
- HCM N/A
- SAM N/A
- Revenue Next Year
- HCM $15.49
- SAM $1.10
- P/E Ratio
- HCM $5.61
- SAM $31.29
- Revenue Growth
- HCM N/A
- SAM 2.46
- 52 Week Low
- HCM $11.51
- SAM $185.34
- 52 Week High
- HCM $21.50
- SAM $329.55
- Technical
- Relative Strength Index (RSI)
- HCM 39.12
- SAM 48.06
- Support Level
- HCM $14.86
- SAM $216.46
- Resistance Level
- HCM $15.34
- SAM $227.78
- Average True Range (ATR)
- HCM 0.32
- SAM 6.62
- MACD
- HCM -0.06
- SAM -0.45
- Stochastic Oscillator
- HCM 7.79
- SAM 29.85
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
About SAM Boston Beer Company Inc. (The)
Boston Beer is a top player in high-end malt beverages and adjacent categories in the US, with strong positions in craft beer, flavored malt beverages, hard cider, and hard seltzer. The bulk of volume and revenue is concentrated in four brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly. Beverages are produced using a hybrid model leveraging both in-house capacities and third-party breweries through contract arrangements. While the firm is required to use distributors to reach end markets, including retailers and on-premises operators, it also employs 500 internal sales representatives to educate the market about its products. The firm generates almost all sales in the US.